Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
Real-time Quote. Real-time Tradegate - 12/10 07:15:21 am
85.15 EUR   +4.02%
05:58aSanofi shares rally on new margin goals, narrow drug focus
RE
04:17aEUROPE : European shares dip on trade uncertainty
RE
02:48aSanofi to Get Out of Diabetes Research -- WSJ
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Exclusive: Sanofi's strategy boss to leave as CEO readies revamp

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/22/2019 | 08:47am EST
The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine,

Sanofi most senior strategy boss is set to leave by the end of the month, according to a memo seen by Reuters, in the first major management change under new chief executive Paul Hudson as he shakes up the firm's priorities.

Muzammil Mansuri, head of strategy and business development and member of the French drugmaker's executive committee, will be retiring from the company, according to the note from Hudson sent to staff on Wednesday.

A spokesman for Sanofi confirmed the decision.

Hudson, who took over as CEO on Sept. 1, is leading a strategic review and is expected to unveil the company's plan for the coming years at an investor day in Cambridge, Massachusetts, on December 10.

Mansuri had joined Sanofi in 2016 from Gilead Sciences where he was in charge of research and development strategy and corporate development.

Hudson said in the memo that Alban de la Sabliere, currently head of business development, and Laurent Van Lerberghe, head of strategy, would take on more responsibilities as of Dec. 1 and report directly to him.

Even though the group's new strategy is still in the works, Hudson has made no secret that significant changes were underway.

"I am bringing a little sense of urgency and prioritisation. I have set a tone already that we can move a little bit faster," Hudson told reporters in October.

"I think we have the right level of resources although perhaps not always in the right place."

Sources have told Reuters Sanofi was contemplating a joint venture or an outright sale among options for its consumer healthcare unit.

An initial public offering (IPO) of the business, which could be worth around $30 billion according to two sources familiar with the matter, is also potentially on the cards though they cautioned that no final decision had been made.

Analysts have argued a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion euros ($5.20 billion), would enable the group to invest more in internal research.

The future of Sanofi's ailing diabetes business - under constant pricing pressure in the United States, the world's largest health market - is also under the spotlight.

($1 = 0.9042 euros)

(Editing by Christian Lowe and Elaine Hardcastle)

By Matthias Blamont

Stocks treated in this article : Sanofi, Gilead Sciences
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES -0.22% 66.93 Delayed Quote.7.00%
SANOFI 4.03% 85.16 Real-time Quote.8.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
05:58aSanofi shares rally on new margin goals, narrow drug focus
RE
04:17aEUROPE : European shares dip on trade uncertainty
RE
02:48aSanofi to Get Out of Diabetes Research -- WSJ
DJ
02:48aMerck, Sanofi Push To Add Cancer Drugs -- WSJ
DJ
12/09DAVID KLEIN : Top Company News of the Day
DJ
12/09Big Drugmakers Push Deeper Into Cancer Treatment -- 4th Update
DJ
12/09Sanofi ends research in diabetes, narrows units to spur profit
RE
12/09Health Care Down Amid Mixed Reactions To Cancer-Drug Acquisitions -- Health C..
DJ
12/09SANOFI : Maker of World's Biggest Insulin, to Exit Diabetes Research
DJ
12/09SANOFI : Maker of World's Biggest Insulin, to Exit Diabetes Research
DJ
More news
Financials (EUR)
Sales 2019 36 589 M
EBIT 2019 9 519 M
Net income 2019 4 318 M
Debt 2019 14 880 M
Yield 2019 3,84%
P/E ratio 2019 24,7x
P/E ratio 2020 17,6x
EV / Sales2019 3,21x
EV / Sales2020 3,05x
Capitalization 103 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 91,85  €
Last Close Price 81,86  €
Spread / Highest target 25,8%
Spread / Average Target 12,2%
Spread / Lowest Target -8,38%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Chief Medical & Digital Officer
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI8.19%113 562
JOHNSON & JOHNSON8.78%369 778
ROCHE HOLDING AG25.45%262 410
MERCK AND COMPANY16.28%225 880
PFIZER-12.21%212 068
NOVARTIS22.87%209 056